Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 11/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642108 | 0.88 | AR (0.53) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL769392 | 0.83 | MAOB (0.42) | ALDH1A1KDM4EUSP2MAOAMAOB | |
| SCHEMBL23143199 | 0.80 | XDH (0.51) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL2115285 | 0.79 | XDH (0.48) | ALDH1A1KDM4EUSP2 | |
| SCHEMBL1762094 | 0.78 | ALDH1A1 (0.63) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL2094284 | 0.78 | ALDH1A1 (0.63) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL5029109 | 0.78 | ALDH1A1 (0.63) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL30730992 | 0.78 | ALDH1A1 (0.63) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL4709886 | 0.77 | APP (0.56) | MAOAMAOB | |
| SCHEMBL3817177 | 0.76 | KDM4E (1.00) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2804868-B1 | PYRAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2016061344-A1 | GSK3 INHIBITORS AND THEIR USES | MIRX PHARMACEUTICALS LLC (US) | 2016-04-21 | — | — | WO | disclosed |
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| EP-2024333-A2 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007125331-A2 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125331-A2 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | PKD2, PKD1, AADAT | ALDH1A1 1832/4885KDM4E 757/4885USP2 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.